Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03929-9
Abstract: Fedratinib (SAR302503, TG101348) is an orally administered Janus kinase (JAK) 2-selective inhibitor that is being developed for the treatment of patients with myelofibrosis (MF). The objectives of this analysis were to develop a population pharmacokinetic… read more here.
Keywords: fedratinib; polycythemia vera; vera essential; patients myelofibrosis ... See more keywords
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
Sign Up to like & getrecommendations! Published in 2022 at "Leukemia research"
DOI: 10.1016/j.leukres.2022.106809
Abstract: Patients with polycythemia vera (PV) and essential thrombocythemia (ET) have increased thrombotic risk. This retrospective, real-world analysis of Medicare patients (age ≥ 65 years) newly diagnosed with high-risk PV or intermediate-/high-risk ET compared mortality risk among… read more here.
Keywords: risk; polycythemia vera; thrombotic events; mortality risk ... See more keywords
Polycythemia vera and essential thrombocythemia: algorithmic approach
Sign Up to like & getrecommendations! Published in 2018 at "Current Opinion in Hematology"
DOI: 10.1097/moh.0000000000000402
Abstract: Purpose of review To describe an algorithm-based approach, whenever available, to the diagnosis, the risk stratification criteria informing therapy and the current management of polycythemia vera and essential thrombocythemia. Recent findings Description of recurrent genetic… read more here.
Keywords: polycythemia vera; vera essential; approach; thrombocythemia ... See more keywords
Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis Patients
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13030482
Abstract: Simple Summary Current diagnosis of myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and essential thrombocythemia (ET), is controversial due to limitations associated with the lack of reproducibility, subjectivity and the presence of common somatic mutations… read more here.
Keywords: thrombocytosis patients; polycythemia vera; vera essential; secondary thrombocytosis ... See more keywords